SEC Form 4 · accession 0001250853-18-000093
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph S McCracken
Director
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 7:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.00 | Jun 22, 2018 | A | 10,000 | A | — | Jun 21, 2028 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option will vest in four equal quarterly installments following the grant date.